Trametinib
| CAS No. | 871700-17-3 |
|---|---|
| MDL No. | MFCD17215075 |
| MF | C26H23FIN5O4 |
| MW | 615.40 |
| InChI Key | LIRYPHYGHXZJBZ-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Trametinib is a pyridopyrimidine used as a dimethyl sulfoxide addition compound for treating unresectable or metastatic melanoma with BRAF V600E or V600K mutations in patients without prior BRAF inhibitor treatment. It functions as an MEK inhibitor, antineoplastic agent, anticoronaviral agent, and geroprotector. It is also an organofluorine, organoiodine compound, acetamide, ring assembly, cyclopropane, and aromatic amine.
| CAS No. | 871700-17-3 |
|---|---|
| Product Name | Trametinib |
Biological Targets
MAP2K1·MAP2K2
Associated Conditions
gastrointestinal stromal tumor·epithelioid hemangioendothelioma·Cerebral arteriovenous malformation·hepatocellular carcinoma·amyotrophic lateral sclerosis·
* The information provided here is compiled from public sources and is for reference only.
